
|Articles|November 1, 2003
New drug targets considered for erectile dysfunction
Author(s)Robert H. Carlson
Paris-Basic research in erectile dysfunction therapy is being hamperedby the attitude of some funding bodies that phosphodiesterase type-5 inhibitorsalone have solved all problems, according to a special committee convenedat the 2nd International Consultation on Erectile and Sexual Dysfunctionshere.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sildenafil cream for female sexual arousal disorder available to prescribe in select states
2
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
3
FDA approves ProVee System for benign prostatic hyperplasia
4
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
5















